Clinical Trial Update: A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 study of lumacaftor in combination with ivacaftor in cystic fibrosis patients aged 12 and older who are homozygous for the F508del CFTR mutation complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• Lumacaftor (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | Phase 3 | Status: COMPLETED | Results posted: 2015-08-31